News

August 15, 2016

Claritas Genomics announces two new phenotypes to our Pediatric Neurology Region of Interest test as well as updates to pre-existing gene lists.

  • The Autism gene list includes 196 genes specifically curated to autism.
  • The Developmental Delay/Intellectual Disability gene list includes 340 genes relevant to DD/ID.

These two new sub-phenotypes offer providers more powerful testing for their patients with complex pediatric neurology phenotypes. In addition,...

August 05, 2016

Claritas Genomics has launched the Nephrotic Syndrome Region of Interest (NS-ROI). The NS-ROI sequences 42 genes relevant to Nephrotic Syndrome, an increase of 13 genes from the original Nephrotic Syndrome Panel, which is now discontinued. 

The NS-ROI is built on the Claritas Clinical Exome platform, which allows expansion into any Claritas exome product, and allows rapid changes to the gene list as discoveries in the field occur.  Additionally, clients can request raw data in the form of VCF and BAM files for further investigation into the patient's exome. Gene...

April 19, 2016

Boston, Massachusetts │ April 19, 2016 – Claritas Genomics today announced the publication of a study demonstrating the superior sensitivity and speed of its proprietary orthogonal sequencing process compared to industry standard practice.  The study, ‘Orthogonal Next Generation Sequencing (NGS) for High Throughput Clinical Diagnostics’  was published today in the online edition of Scientific Reports.  Orthogonal sequencing is the practice of running two gene sequencing technologies in parallel to assist...

April 04, 2016

Marcia Nizzari, MS, CIO will speak at Bio*IT World Conference & Expo 2016 at the Seaport World Trade Center April 5-7. Ms. Nizzari's talk is Thursday, April 7 at 2:30pm and is entitled "A Clinical Genetics Diagnostic System Incorporating Next-Gen Sequencing and Informatics to Advance Pediatric Genetics Care."

The following is the summary of her talk which is included in the Track brochure: 
Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers...

February 17, 2016

Our scientists will be available during the following times to discuss their posters. If you miss these times, visit us at booth 419.

THURSDAY, MARCH 10, 10:30a-12:00p

291- John Thompson, PhD: Two exomes are better than one; Orthogonal NGS for Clinical Diagnostics
Whole exome/genome sequencing studies have revolutionized the diagnosis of genetic disorders. However, typical high-throughput sequencing strategies require Sanger confirmation to meet the exacting demands of clinical diagnostic sequencing. To address this gap, we tested orthogonal next-...

January 21, 2016

CAMBRIDGE, Massachusetts; January 21, 2016 – 2015 was a year of advances for Claritas Genomics continuing the company’s mission to advance precision care for children. The company secured $15 million for its Series B, launched new diagnostic gene tests, announced a partnership with the world’s largest rare disease patient advocacy organization, sequenced 19,600 research exomes, announced its Scientific Advisory Board and became one of only eight clinical laboratories in the US to be awarded the International Standardization Organization’s (ISO) 15189 accreditation by the American...

January 07, 2016

BOSTON, Massachusetts | January 7, 2016 – Claritas Genomics, Inc., is pleased to announce that they have been granted ISO 15189 accreditation (Certificate 3712.01) by the American Association for Laboratory Accreditation (A2LA), after a thorough assessment and review of its quality management system and competence to perform over 100 molecular diagnostic tests on the Claritas menu. 

Claritas decided to pursue ISO certification shortly after spinning out of Boston Children’s Hospital in February 2013.  “We felt the complex nature of molecular diagnostics warranted the rigor...

January 05, 2016

BOSTON / PRNewswire-USNewswire/ -- Claritas Genomics, Inc., announced today the formation of a Scientific Advisory Board (SAB) comprised of physicians and scientists recognized as leading experts in the areas of medical genetics, neurology, oncology, pharmacology, translational medicine and drug development. The SAB's mission will be to provide valuable scientific and clinical insights, along with strategic guidance, as Claritas seeks to advance its pediatric precision medicine solutions for institutions around the world.

"We are honored to welcome such an outstanding...

November 17, 2015

Patrice Milos, President and CEO of Claritas Genomics, will speak at the Personalized Medicine World Conference to be held January 24-27, 2016 in Mountain View California. Dr. Milos will be a key speaker in the featured session "Diagnosis and Management of Rare Disease". This session will focus on problem solving through barriers that exist for millions of patients worldwide who have rare diseases.

Read more at the PMWC international website.

Featured Session: Diagnosis & Management of Rare...

About Claritas

Claritas Genomics serves children affected with complex genetic disorders by providing timely and accurate results, resolving families’ long search for answers. By combining clinical expertise of the world’s best pediatric specialists with innovative platform solutions, Claritas is working to improve patient care and enable new discoveries. We are committed to the highest quality and accessibility of information and our interpretive services and unique approach to reporting set the standard for reliably and clearly communicating genetic information.

Now is the time to integrate genomics into clinical practice to inform, guide and improve medical treatment for kids around the world.